Expression of an Immunomodulatory Protein Known as Progesterone Induced Blocking Factor (PIBF) Does Not Correlate With First Trimester Spontaneous Abortions in Progesterone Supplemented Women

No abstract is available for this paper.

• Publication year

  1997

• Venue

  American Journal of Reproductive Immunology

• Publication date

  1997-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1600-0897.1997.tb00239.xPMID 9161642
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evidence that the Expression of Progesterone‐Induced Blocking Factor by Maternal T‐Lymphocytes Is Positively Correlated with Conception

  1997cited by this paper
• Enhancement of the Expression of Progesterone Receptor on Progesterone‐Treated Lymphocytes After Immunotherapy in Unexplained Recurrent Spontaneous Abortion

  1996cited by this paper
• Progesterone Induced Blocking Factor Seen in Pregnancy Lymphocytes Soon After Implantation

  1996cited by this paper
• The Immunological Pregnancy Protective Effect of Progesterone Is Manifested via Controlling Cytokine Production

  1996cited by this paper
• The Expression of a Progesterone‐Induced Immunomodulatory Protein in Pregnancy Lymphocytes

  1995cited by this paper
• Synthesis of T helper 2-type cytokines at the maternal-fetal interface.

  1993cited by this paper
• Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon?

  1993cited by this paper
• Immunosuppression by Progesterone in Pregnancy

  1992cited by this paper
• Progesterone Suppression of Pregnancy Lymphocytes Is not Mediated by Glucocorticoid Effect

  1990cited by this paper
• Reactivity of lymphocytes to a progesterone receptor-specific monoclonal antibody.

  1990cited by this paper
• Heterogeneity of cytokine secretion patterns and functions of helper T cells.

  1989cited by this paper
• Progesterone receptors in lymphocytes of liver-transplanted and transfused patients.

  1989cited by this paper
• Oocyte donation by gamete intra-fallopian transfer to amenorrhoeic and cycling patients given replacement steroids.

  1989cited by this paper
• Immunoregulatory effects of a suppressor factor from healthy pregnant women's lymphocytes after progesterone induction.

  1989cited by this paper
• ELISA test for the detection of an immunological blocking factor in human pregnancy serum.

  1989cited by this paper
• The mechanism of the inhibitory effect of progesterone on lymphocyte cytotoxicity: I. Progesterone-treated lymphocytes release a substance inhibiting cytotoxicity and prostaglandin synthesis.

  1985cited by this paper
• Anti‐Fetal Allo‐Antibody in the Pregnant Female

  1983cited by this paper
• Indispensability of the human corpus luteum in the maintenance of early pregnancy. Luteectomy evidence.

  1978cited by this paper
• Suppression of maternal responsiveness to paternal antigen by maternal plasma.

  1975cited by this paper
• Specific plasma factors blocking human maternal cell-mediated immune reaction to placental antigens.

  1973cited by this paper
• Effect of Multiparity on Human Maternal Hypersensitivity to Foetal Antigen

  1973cited by this paper

• Recurrent Pregnancy Loss

  2025cites this paper
• Debate: Should Progesterone Supplements Be Used? Yes

  2014cites this paper
• Mifepristone causing complete remission of rapidly advancing leukemia with measurement of progesterone-induced blocking factor.

  2014cites this paper
• Luteal phase support for in vitro fertilization-embryo transfer--present and future methods to improve successful implantation.

  2012cites this paper
• A practical approach to the prevention of miscarriage: part 2--active immunotherapy.

  2010cites this paper
• Progesterone receptor antagonist therapy has therapeutic potential even in cancer restricted to males as evidenced from murine testicular and prostate cancer studies.

  2010cites this paper
• A comparison of three types of therapies for three different ovulation disorders in establishing pregnancies and evaluation of laboratory parameters that could influence the outcome.

  2010cites this paper
• Mifepristone treatment improves length and quality of survival of mice with spontaneous leukemia.

  2009cites this paper
• Luteal Phase Support in assisted reproductive technology treatment: focus on Endometrin® (progesterone) vaginal insert

  2009cites this paper
• A practical approach to the prevention of miscarriage: Part 1--Progesterone therapy.

  2009cites this paper
• Support for the hypothesis that successful immunotherapy of various cancers can be achieved by inhibiting a progesterone associated immunomodulatory protein.

  2009cites this paper
• Mifepristone may halt progression of extensively metastatic human adenocarcinoma of the colon - case report.

  2009cites this paper
• Expression and modulation of progesterone induced blocking factor (PIBF) and innate immune factors in human leukemia cell lines by progesterone and mifepristone

  2007cites this paper
• Should progesterone supplements be used?: – Against

  2007cites this paper
• Should progesterone supplements be used?: – For

  2007cites this paper
• Marked improvement of intractable arthritic pain in a woman with rheumatoid arthritis with sympathomimetic amine treatment despite previous failure with standard therapy and possible implications for last trimester unexplained fetal demise--case report.

  2007cites this paper
• Mifepristone treatment improves length and quality of survival of mice with spontaneous lung cancer.

  2007cites this paper
• Evidence that progesterone receptor antagonists may help in the treatment of a variety of cancers by locally suppressing natural killer cell activity.

  2007cites this paper
• Progesterone‐Modulated Phosphatidylserine Externalization in Apoptosis and Activation of Jurkat Cells

  2006cites this paper
• Recurrent miscarriage and embryonic loss.

  2005cites this paper
• Changes in progesterone-induced-blocking-factor expression rates following mifepristone administration in termination of pregnancy at 5 to 8 weeks

  2005cites this paper
• Maternal-Fetal Aspects of Autoimmune Disease

  2005cites this paper
• CD83+ Monocyte‐Derived Dendritic Cells are Present in Human Decidua and Progesterone Induces Their Differentiation In Vitro

  2005cites this paper
• Th1 and Th2 cytokine profiles in recurrent aborters may merely reflect the progesterone status.

  2002cites this paper
• Shifts in the TH1/TH2 balance during human pregnancy correlate with apoptotic changes.

  1998cites this paper